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Objective
To describe the temporal trends in nephrectomy practice and
outcomes for English patients with renal cell carcinoma
(RCC).
Patients and Methods
Adult RCC nephrectomy patients treated between 2000 and
2010 were identified in the National Cancer Data Repository
and Hospital Episode Statistics, and followed-up until date of
death or 31 December 2015 (n = 30 763). We estimated the
annual frequency for each nephrectomy type, the hospital and
surgeon numbers and their case volumes. We analysed short-
term surgical outcomes, as well as 1- and 5-year relative
survivals.
Results
Annual RCC nephrectomy number increased by 66% during
the study period. Hospital number decreased by 24%, whilst
the median annual hospital volume increased from 10 to 23
(P < 0.01). Surgeon number increased by 27% (P < 0.01),
doubling the median consultant number per hospital. The
proportion of minimally invasive surgery (MIS)
nephrectomies rose from 1% to 46%, whilst the proportion of
nephron-sparing surgeries (NSS) increased from 5% to 16%,
with 29% of all T1 disease treated with partial nephrectomy
in 2010 (P < 0.01). The 30-day mortality rate halved from
2.4% to 1.1% and 90-day mortality decreased from 4.9% to
2.6% (P < 0.01). The 1-year relative survival rate increased
from 86.9% to 93.4%, whilst the 5-year relative survival rate
rose from 68.2% to 81.2% (P < 0.01). Improvements were
most notable in patients aged ≥65 years and those with T3
and T4 disease.
Conclusions
Surgical RCC management has changed considerably with
nephrectomy centralisation and increased NSS and MIS. In
parallel, we observed significant improvements in short- and
long-term survival particularly for elderly patients and those
with locally advanced disease.
Keywords
#KidneyCancer, centralisation, nephrectomy, postoperative
outcomes, renal cancer, survival
Introduction
Incidence of RCC has been increasing worldwide year-on-
year by 3–4% and accounts for ~3% of all new cancer
diagnoses in the UK [1,2]. Historically, RCC survival in
England has lagged behind many other European countries
[3,4]. Initiatives to improve outcomes through surgical service
centralisation, reducing diagnostic delay, and increasing
multidisciplinary team involvements in patient care were
introduced in the Improving outcomes in urological cancer
Guidance in 2002 [5]. In parallel, there is a growing move
towards the use of nephron-sparing surgery (NSS) and
laparoscopic or robotic nephrectomy [6,7]. It is not currently
known how adoption of these guidelines and practices has
impacted patient outcomes, particularly on a nationwide level.
Many population-based studies examining RCC survival have
focused on patients irrespective of treatment modality and
may include those who received no active treatment [8–10].
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Interpretation of findings from these studies is however
challenging, as nephrectomy is often considered the only
potentially curative treatment for RCC and inclusion of other
treatment modalities may dilute the specific effect of changes
in surgical practice. In the present study, we describe the
changes to RCC nephrectomy activity and service provision
in England in recent years and investigate temporal trends in
short- and long-term outcomes with a particular focus on
survival.
Patients and methods
Data
Data extract was supplied by Public Health England National
Cancer Registration and Analysis Service (NCRAS) and
contains fields from both the National Cancer Data
Repository (NCDR) and Hospital Episode Statistics (HES)
Admitted Patient Care. The NCDR contains tumour level
records submitted by the eight English Cancer Registries,
together with survival information sourced from the Office
for National Statistics (ONS) [11]. HES is a major
administrative database containing details of all patients
admitted to NHS hospitals in England [12]. Together,
hospital, patient, and tumour level information can be
directly extracted or derived from the supplied linked
database. Individual data fields and their source are described
in Table S1. Ethics approval was granted by the National
Research Ethics Committee (reference 15/EM/0340) and
Confidentiality Advisory Group (reference 15/CAG/0169).
Exposure variables
We included all patients diagnosed with RCC and treated
with either radical or partial nephrectomy between 2000 and
2010, regardless of tumour stage. We excluded those aged
≤17 years at the time of surgery, as well as those diagnosed
with upper tract urothelial carcinoma. Patients treated with
nephroureterectomy, nephrectomy of transplanted kidney or
focal therapies were also excluded from our study population.
The cohort was identified using the International Statistical
Classification of Diseases and Related Health Problems 10th
revision (ICD10) code and Office of Population Censuses and
Surveys Classification of Interventions and Procedures version
4 (OPCS4) code (Table S2).
Type of nephrectomy and surgical access were derived from
HES procedure codes. Operative caseloads were calculated
based on the number of nephrectomies performed per annum
by the responsible hospital as recorded in HES. Within the
NHS, a Trust may manage more than one local hospital. In
our analysis, we treat all hospitals within the same Trust as a
single organisation. Similarly, we calculated surgeons’
operative caseloads using the same method. To account for
potential coding errors of the responsible clinician, we only
included surgeons recorded as having performed five or more
nephrectomies per year.
Patient demographics including age, sex, ethnicity, and
socioeconomic deprivation together with admission details
such as admission method and waiting time were extracted
directly from the NCDR or HES. We tabulated patient
comorbidities by using the Royal College of Surgeons
Charlson Score [13]. ICD10 diagnosis codes recorded in HES
from the index nephrectomy admission and up to 1 year
prior were used to estimate the number of comorbid
conditions each patient had at the time of the operation.
Diagnoses from the index hospital admission were excluded if
they were likely to be complications of surgery rather than
comorbid conditions.
Outcome variables
We calculated the population nephrectomy rate by dividing
the total number of nephrectomies in England per annum
over the mid-year English population estimate as published
by the ONS [14]. The total number of nephrectomies was
compared with the number of RCCs registered in England to
provide the proportion of RCCs resected each year [15].
Re-admissions were identified if patients had a new admission
within 30 days of discharge from the index nephrectomy
admission and a concurrent emergency status recorded as the
method of admission. Length of stay was calculated by taking the
differences between date of nephrectomy and date of discharge.
Short-term surgical outcomes including infection,
haemorrhage and transfusion were derived from the ICD10
diagnosis fields in HES. Survival time was calculated from
date of surgery until date of death or 31 December 2015. In-
hospital mortality was derived if patient was recorded as
having died in the HES discharge method field.
Analysis
We summarised time trend by calculating the annual average
percent change (AAPC) across the study period using the
Joinpoint Regression Program [16,17]. P values <0.05 were
considered statistically significant. All other statistical analyses
were performed using Stata Statistical Software: release 14
(StataCorp., College Station, TX, USA) [18].
We estimated relative survival, defined as the ratio of the
observed survival in our cohort to the expected survival in
the general population. It is an estimate of the survival rate
that would be observed if patients could only die from their
RCC and is analogous to cause-specific survival. A major
advantage of measuring relative survival is that cause of
death, which may be unreliable in registry data, is not
required. Relative survival rates were capped at 100%. We
used English population life tables stratified by age, sex and
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calendar year to calculate expected survival rates and these
were available online from the Cancer Survival Group at the
London School of Hygiene and Tropical Medicine [19]. We
used rates from 2009 for years beyond 2009. Relative survival
rates were estimated using the strs package in Stata [20]. To
avoid possible confounding caused by shifts in patients’ age
profile, we estimated relative survival separately for age
groups ≤64, 65–74, and ≥75 years, and standardised to the
age distribution of our incident cohort in 2010. Amongst
patients with observed stage, subgroup analyses stratified by T
stage were performed on patients with localised disease,
excluding those recorded as having nodal or distant
metastases (N1 or M1 or above).
Results
A total of 30 763 adult RCC nephrectomies were performed
in England between 2000 and 2010, with a median follow-up
of 9.3 years. Data fields from HES were largely complete
except for ethnicity and waiting time, recorded in 92.6% and
91.4% of the patients, respectively. Tumour level data from
the NCDR were less complete with 41.4% of patients having
tumour size recorded and 46.7% of patients with T stage data.
Changes in nephrectomy activity
The annual number of nephrectomies in England increased
overall by 65.7% from 2211 in 2000 to 3664 in 2010
(Fig. 1A). In the same time period, the crude annual
nephrectomy rate in the general population increased from
4.5 to 7.0 per 100 000 people per year, an average annual
increase of 4.9% (P < 0.01) (Table 1). Looking specifically at
RCC registered in England, 50.5% of those diagnosed in 2000
had their cancer resected, increasing to a peak of 55.9% for
those diagnosed in 2008. There appeared to be broadly
similar increasing trends for men and women and for
patients aged 18–64 and 65–74 years. Use of nephrectomy for
patients aged ≥75 years appeared stable at ~30%.
Partial nephrectomy was increasingly utilised, accounting for
16.1% of all RCC surgery and 29.0% of all T1 disease by the
end of the study (P < 0.01). Use of minimally invasive
surgery (MIS) increased to 46.4% of all RCC nephrectomies
by 2010 (P < 0.01).
Changes in service provision
The number of hospitals performing any RCC nephrectomy
decreased by one-quarter over the study period, an average
reduction of 2.8% per annum (P < 0.01) (Table 2). This decline
was only seen for hospitals performing radical nephrectomy,
whilst the number of hospitals performing partial nephrectomy
increased on average by 5.9% per year (P < 0.01). The number
of hospitals performing MIS nephrectomy also increased, with
118 of the 136 (86.8%) hospitals performing any nephrectomy
in 2010 adopting the technique. The median hospital
nephrectomy volume increased from 10 per hospital in 2000 to
23 per hospital in 2010 (P < 0.01), with median partial
nephrectomy volume increasing from one to five (P < 0.01)
and laparoscopic or robot-assisted nephrectomy volume
increasing from one to 12 (P < 0.01).
The number of surgeons performing RCC nephrectomy
increased overall regardless of the type of nephrectomy or
access (P < 0.01) (Table 2). The most pronounced increase
was seen for surgeons performing MIS nephrectomy, with an
average increase of 51.8% per annum (P < 0.01). Consultant
teams also expanded with the median number of surgeons
per hospital increasing two-fold over the study period (P <
0.01). The median nephrectomy volume per surgeon grew
from 7 to 10.5 (P < 0.01). Similar growths were seen across
different types of nephrectomy and approach.
Despite the year-on-year growth in the number of
nephrectomies performed in England, we observed a
reduction in the number of nephrectomy-performing
hospitals and an increase in the number of nephrectomy-
performing surgeons, with paralleled increase in both hospital
and surgeon nephrectomy volumes, suggestive of service
centralisation.
Changes in patient characteristics and outcomes
The mean age and sex distribution remained stable during
the 11-year period and the proportion of White patients
decreased from 95.7% to 94.1% (P < 0.01) (Table S3). The
proportion of patients with multiple recorded comorbidities
increased significantly and by 2010, 46.8% of RCC
nephrectomy patients had one or more recorded
comorbidities (P < 0.01).
Of those patients with available tumour data, the mean
tumour size decreased from 71.5 to 64.5 mm (P < 0.01). An
increasing proportion of nephrectomies involved smaller
tumours (T1) and localised disease (Stage I) accounting for
46.2% and 39.0%, respectively, in 2010 (P < 0.01).
The median time patients waited for their operation increased
overall (P = 0.01), and appears to have been stable between
22 and 25 days since 2003 (Table 3). The proportion of
nephrectomies performed under emergency admission
decreased from 9.0% to a low of 3.0% in 2010 (P < 0.01). The
median length of stay decreased regardless of the type of
nephrectomy or approach, reducing overall from 8 days in
2000 to 5 days in 2010 (P < 0.01). However, the percentage
of patients re-admitted as an emergency within 30 days of
discharge rose from 8.1% to 10.5% (P < 0.01). There was no
significant change in postoperative infection or haemorrhage
rates, but a significant reduction in transfusion rates was
noted, with only 0.4% of patients in 2010 requiring
transfusion compared to 6.6% in 2000 (P < 0.01).
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Figure 1B shows the trend in short-term mortality
throughout the study period. The 30-day mortality rate
decreased from 2.4% to 1.1% (P < 0.01). Similar reductions
were seen for 90-day mortality (p<0.01) and in-hospital
mortality (P < 0.01), which had an average year-on-year
decrease of 6.6% and 8.0%, respectively. These were in
keeping with the increase in 30- and 90-day age-standardised
relative survival rates, which saw absolute increases of 1.1%
and 2.2%, respectively (P < 0.01). The reduction in mortality
was most prominent in patients aged ≥65 years regardless of
the follow-up period (Table S4).
The 1- and 5-year age-standardised relative survival for all
RCC nephrectomies increased to 93.4% and 81.2%,
respectively by 2010, from 86.9% and 68.2%, respectively in
2000 (P < 0.01) (Fig. 2). Improvements in relative survival
seemed primarily driven by patients with locally advanced
disease (T3 and T4), for whom 1- and 5-year relative survival
increased from 83.9% to 91.8% (P < 0.01) and from 59.0% to
71.6%, respectively (P = 0.01) (Table 4).
Discussion
Between 2000 and 2010 the annual number of RCC
nephrectomies performed in England increased by nearly
66%, with a greater proportion of RCCs treated surgically.
Nephrectomy centralisation is evident with increasing median
case volumes for both hospitals and surgeons. There was also
a rapid increase in the use of NSS and MIS. During this
period, postoperative outcomes and long-term survival rates
showed significant trends of improvement.
Changes to nephrectomy practice are in part secondary to the
shift in tumour stage distribution and the adoption of NSS as
a standard for early stage disease. Increasing detection of
small renal tumours have led to the increase in RCC
incidence, reflected in the growing proportion of T1 disease
in our present cohort [21]. Partial nephrectomy is also
increasingly the standard surgical treatment for T1 renal
tumours [22] and emerging as an acceptable alternative for
selected T2 disease [23]. Patients previously not candidates
for radical treatment due to risk of renal failure may now be
considered for NSS, where further renal function
deterioration is mitigated through the preservation of renal
parenchyma [24].
We tracked the centralisation of RCC nephrectomy, reflecting
similar trends in other established healthcare systems [25].
However, we observed centralisation occurring across the
board for all nephrectomy types, in contrast to
recommendations that focused primarily on the 20% of RCC
cases where patients present with bilateral disease, resectable
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Figure 1 A. Total number of RCC nephrectomies performed in England and B. post-nephrectomy deaths in each calendar year.
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metastatic disease, hereditary papillary or von Hippel-Lindau
disease, and for those suitable for NSS or whose tumours
have invaded the large veins [5]. This may be secondary to
hospital mergers and the potential reduction in costs, and
there also appears to be a trend of improving outcomes in
nephrectomy centralisation [26–28]
Whilst the use of NSS and MIS techniques has increased
rapidly in the past decade, there may still be a delay in
England in adopting surgical innovations. At its peak, partial
nephrectomy was performed in 16% of all RCC
nephrectomies, behind the 31–32% reported in other
European and USA series over the same period [29–31]. It is
unclear whether stage distributions were comparable across
the different series, but the number and proportion of partial
nephrectomies estimated from our present data are broadly
consistent to estimates from an earlier British study [32]. The
difference is even more remarkable when comparing only T1
disease, where 29% of patients in England were treated with
NSS compared to 57% in a multinational multicentre study
[33], although institutional data may not fully represent
nationwide practice, particularly as hospital level factors can
significantly influence the utilisation of partial nephrectomy
[34].
Historical studies showed conflicting results for short-term
nephrectomy morbidity and mortality trends over time
[26,35]. We found clear improvements in surgical mortality,
with the 30-day mortality rate decreasing to 1.1% in 2010,
similar to the 0.9–2.7% reported by other countries during
the same time period [36–38]. The greatest improvements
were seen in elderly patients aged ≥65 years, suggesting
greater safety in surgery with reduced outcome inequality for
patients of different ages and were consistent with the
improvements seen in other urological procedures [39].
Long-term post-nephrectomy RCC outcomes have so far been
poorly reported at national levels. We observed a substantial
survival increase at 1 and 5 years after surgery, to levels
similar to the cancer-specific survival rates reported by other
series for patients treated during the same periods, even when
T stage is taken into consideration [40,41]. Advances in
systemic therapy or other host factors, such as progressively
fitter patients, may have contributed to the improvement.
However, adjuvant or neoadjuvant therapy have not
traditionally been advocated for patients with locally
advanced disease, a group we observed the most significant
survival increase, which would suggest that the improving
trend is in part due to the improvements in surgical quality
and care.
To the best of our knowledge, this is the first study using
routinely collected data with whole population coverage to
examine long-term survival specifically in patients with RCC
treated surgically. Results from the BAUS nephrectomy
dataset have previously been published and reported on
outcomes in periods beyond those covered in the present
study [32]. A similar number of RCC nephrectomies,
proportion of NSS, length of stay, and 30-day mortalities
were observed between our estimates and the BAUS study,
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particularly when time trends are taken into consideration.
However, the main advantage of our present study is the
large, unselected sample with mandatory reporting. Case
ascertainment from the English cancer registries and the
NCDR has also been estimated to be >98%, compared to 80%
for the BAUS dataset [42]. In addition, the NCDR and HES
provide data with long follow-up duration, not currently
available through the BAUS dataset, and capture the changing
RCC landscape and trend in nephrectomy activities in
England.
The limitations are most notably the inconsistency in coding,
which may be dependent on clinical coders and subject to
changes in government policy. Administrative data such as
HES were initially established primarily for reimbursement
purposes and therefore do not record clinical parameters that
may be relevant to nephrectomy outcome, e.g. ischaemic
time. We were also unable to identify and adjust for disease
recurrence or use of systemic therapy, and these may have
implications on intermediate- and long-term outcomes. A
significant proportion of stage data were missing in our
present cohort and results should be interpreted taking this
into consideration. Extensive work has led to improvements
in data completeness and accuracy in the NCDR and HES,
and use of these data therefore remains justified particularly
when linkage between the two provides complementary
information that compensates each other’s shortcomings. We
were also only able to analyse data from patients treated up
to 2010 and this may not reflect contemporary practice.
Shift in disease stage, service centralisation, and both surgical
and non-surgical innovations, likely all contributed to the
survival increase. Future studies should focus on quantifying
each factor’s influence on the improvements. Linkage of data
between national and local specialty databases should provide
additional clinical parameters for more comprehensive
analyses, whilst maintaining the statistical power of large
datasets. Results will be valuable for the continuous
monitoring of RCC nephrectomy performance and allow
minimum acceptable standards to be set for individual
nephrectomy providers.
In this comprehensive analysis of national data, we found
significant changes to RCC nephrectomy practice in England
over the past decade, with nephrectomy centralisation and
rapid adoption of NSS and MIS. These changes were seen in
parallel with lower postoperative mortality and improved
longer-term survival, although these findings may also reflect
temporal changes in stage case-mix and the increasing use of
effective non-surgical treatments.
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